Table 2 MVD, pMVD, GMP by clinico-pathologic variables and molecular subtypes of breast cancer.
MVD, N = 128 | pMVD, N = 128 | GMP, N = 130 | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
≥ Median | ≥ Median | Present | |||||||||||||
N | % | OR | 95% CI | P | N | % | OR | 95% CI | P | N | % | OR | 95% CI | P | |
Estrogen receptor | |||||||||||||||
Positive | 53 | 50 | Ref | 54 | 51 | Ref | 9 | 8 | Ref | ||||||
Negative | 12 | 57 | 1.4 | 0.5–3.5 | NS | 18 | 86 | 5.9 | 1.6–21.2 | 0.003 | 5 | 24 | 3.5 | 1.0–11.7 | 0.051a |
Progesterone receptor | |||||||||||||||
Positive | 37 | 47 | Ref | 38 | 49 | Ref | 6 | 8 | Ref | ||||||
Negative | 28 | 56 | 1.4 | 0.7–2.9 | NS | 34 | 68 | 2.2 | 1.1–4.7 | 0.032 | 8 | 16 | 2.3 | 0.7–7.0 | NS |
Triple negative | |||||||||||||||
Absent | 54 | 50 | Ref | 54 | 50 | Ref | 9 | 8 | Ref | ||||||
Present | 11 | 55 | 1.2 | 0.5–3.2 | NS | 18 | 90 | 9.0 | 2.0–40.7 | 0.001 | 5 | 25 | 3.7 | 1.1–12.7 | 0.041a |
Tumor stage | |||||||||||||||
T2 | 14 | 37 | Ref | 18 | 47 | Ref | 6 | 16 | Ref | ||||||
T3 | 47 | 59 | 2.4 | 1.1–5.4 | 0.026 | 46 | 58 | 1.5 | 0.7–3.3 | NS | 4 | 5 | 0.3 | 0.1–1.0 | 0.073a |
Histologic grade | |||||||||||||||
1–2 | 45 | 48 | Ref | 49 | 53 | Ref | 6 | 6 | Ref | ||||||
3 | 15 | 56 | 1.3 | 0.6–3.2 | NS | 20 | 74 | 2.6 | 1.0–6.6 | 0.048 | 8 | 30 | 6.2 | 1.9–19.9 | 0.003a |
Molecular subtype | |||||||||||||||
Luminal A | 25 | 47 | 20 | 38 | 2 | 4 | |||||||||
Luminal B | 20 | 50 | 24 | 60 | 3 | 8 | |||||||||
HER2-enriched | 3 | 33 | 6 | 67 | 3 | 33 | |||||||||
Basal-like | 14 | 70 | 19 | 95 | 6 | 30 | |||||||||
Normal breast-like | 2 | 40 | NSa | 2 | 40 | < 0.0005a | 0 | 0 | 0.004a | ||||||
Basal-like | |||||||||||||||
Absent | 50 | 47 | Ref | 52 | 49 | Ref | 8 | 7 | Ref | ||||||
Present | 14 | 70 | 2.7 | 1.0–7.4 | 0.056 | 19 | 95 | 20.1 | 2.6–156 | < 0.0005 | 6 | 30 | 5.4 | 1.6–17.9 | 0.009a |